

Entrepreneurial ID «venture leaders» 2007



Dr. Corinne JOHN

john@redbiotec.ch, +41 44 200 2320

Project: Therapeutics based on multiprotein complexes.

Industry: Biotech

Biography

Please provide a brief biography. Outline the key elements of your entrepreneurial profile, this is a central piece of making your project credible!

If you're not familiar with this, you'll find a lot of examples on the mentoring section of venturelab (<http://www.venturelab.ch/dt/experten.asp>) or former NETS winners (<http://www.new-entrepreneurs.ch/pages/candidates.htm>).

Corinne John is the CEO of the ETH spin-off company Redbiotec AG. She has put together a strong team of experts for the business based on protein complexes for research and drug development. The business idea won several prizes, including the second prize in the Venture 2006 Business Plan competition from McKinsey and ETH. Corinne holds a PhD in Biochemistry from the ETH Zürich. She combines research experience and education from Harvard Medical School and the Ecole Supérieure de Biotechnologie de Strasbourg and strengthened her biochemical background with business classes at ETH Zürich and venturelab.

Company / project

Describe the business opportunity you're pursuing!

In particular, do not forget to include:

- what you're offering
- what is your key differentiator, USP
- your target customers
- your objectives (forecasted revenues, ...)
- the current status and perspectives ("company will be funded in June 06" / "currently employs 5 people and plans to increase to ..." / etc)
- your "call for action" (what are you looking for? money, partners, ...)

Redbiotec AG offers the patented MultiBac technology for the production of protein complexes as they occur in cells. This technology is currently worldwide leading and unique for producing protein complexes. With MultiBac difficult and medically attractive proteins can be produced with their natural partners as protein complexes and thus made accessible for research to understand disease and to develop drugs. Redbiotec has three fields of business: The technology is distributed world wide as kits to academic customers. Secondly, Redbiotec partners up with customers in the pharma and biotech sector to produce tailor-made protein complexes for several steps in the drug discovery process. Finally, the main focus and long-term goal of Redbiotec is the development of innovative biopharmaceuticals based on protein complexes.

Redbiotec AG was founded in November 2006, secured seed financing and carries out projects for industrial customers. The company has currently 3 employees and plans to increase to 6 in 2007. Redbiotec is seeking partners in the pharma and biotech industries and is planning a financial round for fall 2007.